Jubilee

Jubilee Therapeutics is a biopharmaceutical company specializing in the discovery and development of novel small molecule covalent inhibitors for high-value, traditionally undruggable targets. The company leverages a proprietary structure-based drug discovery platform that integrates advanced computational chemistry with structural biology to design precision medicines. Their current pipeline is primarily focused on oncology, with lead programs targeting specific KRas mutations such as G12D and G12V. Additionally, Jubilee is exploring therapeutic applications in neurodegenerative diseases, aiming to address significant unmet medical needs in neurology. Based in Princeton, New Jersey, the company operates in the pre-clinical stage, working to advance its candidates toward clinical trials.